Verrica Historical Income Statement
| VRCA Stock | USD 0.44 0.01 2.22% |
Historical analysis of Verrica Pharmaceuticals income statement accounts such as Interest Expense of 9.9 M, Selling General Administrative of 61.8 M, Total Revenue of 5.6 M or Gross Profit of 3.6 M can show how well Verrica Pharmaceuticals performed in making a profits. Evaluating Verrica Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Verrica Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Verrica Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verrica Pharmaceuticals is a good buy for the upcoming year.
Verrica |
About Verrica Income Statement Analysis
Verrica Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Verrica Pharmaceuticals shareholders. The income statement also shows Verrica investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Verrica Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Verrica Pharmaceuticals. It is also known as Verrica Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Verrica Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Verrica Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.At present, Verrica Pharmaceuticals' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Selling General Administrative is expected to grow to about 61.8 M, whereas Net Interest Income is projected to grow to (7.6 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Depreciation And Amortization | 718K | 836K | 1.3M | 1.3M | Interest Income | 476K | 2.2M | 1.4M | 1.1M |
Verrica Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Verrica Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verrica Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Net Interest Income | (2.5M) | (4.2M) | (1.7M) | 577K | (8.0M) | (7.6M) | |
| Interest Expense | 3.0M | 4.3M | 2.2M | 4.0M | 9.4M | 9.9M | |
| Selling General Administrative | 24.5M | 27.0M | 17.4M | 33.5M | 58.8M | 61.8M | |
| Gross Profit | (229K) | 11.5M | 8.3M | 4.4M | 5.7M | 3.6M | |
| Other Operating Expenses | 40.2M | 42.9M | 30.3M | 70.9M | 73.5M | 38.6M | |
| Operating Income | (40.2M) | (30.9M) | (21.3M) | (65.8M) | (65.9M) | (62.6M) | |
| Net Income From Continuing Ops | (42.7M) | (35.1M) | (24.5M) | (48.3M) | (76.6M) | (72.8M) | |
| Ebit | (39.7M) | (30.8M) | (22.3M) | (63.0M) | (67.2M) | (63.8M) | |
| Research Development | 15.7M | 15.9M | 12.2M | 20.3M | 11.8M | 13.4M | |
| Ebitda | (39.4M) | (30.3M) | (21.6M) | (62.2M) | (65.9M) | (62.6M) | |
| Cost Of Revenue | 229K | 472K | 725K | 746K | 1.9M | 1.9M | |
| Total Operating Expenses | 40.2M | 42.9M | 29.6M | 70.1M | 71.6M | 38.2M | |
| Income Before Tax | (42.7M) | (35.1M) | (24.5M) | (67.0M) | (76.6M) | (72.8M) | |
| Total Other Income Expense Net | (2.5M) | (4.2M) | (3.2M) | (1.2M) | (10.7M) | (10.1M) | |
| Net Income Applicable To Common Shares | (28.2M) | (42.7M) | (35.1M) | (24.5M) | (22.0M) | (23.1M) | |
| Net Income | (45.5M) | (38.9M) | (27.7M) | (67.0M) | (76.6M) | (72.8M) | |
| Income Tax Expense | 2.8M | 3.8M | 3.2M | 668.1K | 768.3K | 729.9K | |
| Interest Income | 521K | 123K | 476K | 2.2M | 1.4M | 1.1M | |
| Depreciation And Amortization | 229K | 472K | 718K | 836K | 1.3M | 1.3M | |
| Reconciled Depreciation | 229K | 472K | 718K | 820K | 1.3M | 1.3M | |
| Non Operating Income Net Other | 1.9M | 520K | 123K | (1.0M) | (917.1K) | (871.2K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verrica Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth (0.83) | Return On Assets | Return On Equity |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.